Lana Hamieh
Overview
Explore the profile of Lana Hamieh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
399
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klonowska K, Giannikou K, Grevelink J, Boeszoermenyi B, Thorner A, Herbert Z, et al.
Am J Hum Genet
. 2023 May;
110(6):979-988.
PMID: 37141891
Tuberous sclerosis complex (TSC) is a neurogenetic disorder due to loss-of-function TSC1 or TSC2 variants, characterized by tumors affecting multiple organs, including skin, brain, heart, lung, and kidney. Mosaicism for...
2.
Giannikou K, Lasseter K, Grevelink J, Tyburczy M, Dies K, Zhu Z, et al.
Genet Med
. 2020 Dec;
23(10):2022.
PMID: 33353975
No abstract available.
3.
Ogorek B, Hamieh L, Hulshof H, Lasseter K, Klonowska K, Kuijf H, et al.
Genet Med
. 2020 May;
22(9):1489-1497.
PMID: 32461669
Purpose: To perform comprehensive genotyping of TSC1 and TSC2 in a cohort of 94 infants with tuberous sclerosis complex (TSC) and correlate with clinical manifestations. Methods: Infants were enrolled at...
4.
Lasseter K, Nassar A, Hamieh L, Berchuck J, Nuzzo P, Korthauer K, et al.
Genet Med
. 2020 Apr;
22(8):1366-1373.
PMID: 32341571
Purpose: Plasma cell-free DNA (cfDNA) variant analysis is commonly used in many cancer subtypes. Cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) has shown high sensitivity for cancer detection. To date, studies...
5.
Hamieh L, Beck R, Le V, Hsieh J
Clin Genitourin Cancer
. 2020 Apr;
18(4):252-257.e2.
PMID: 32291161
Background: Patients with primary refractory metastatic renal cell carcinoma (mRCC) have a dismal prognosis and poor response to subsequent treatments. While there are several approved second-line therapies, it remains critical...
6.
Nassar A, Hamieh L, Gray K, Thorner A, Fay A, Lasseter K, et al.
Mol Cancer Ther
. 2019 Oct;
19(2):690-696.
PMID: 31653662
We previously showed that alterations in mTOR pathway genes were correlated with response to rapalog therapy in metastatic renal cell carcinoma (mRCC), when the analysis focused on extremes of response....
7.
Ogorek B, Hamieh L, Lasseter K, Bagwe S, Machado T, Herranz-Ors C, et al.
Eur Respir J
. 2019 Jul;
54(4).
PMID: 31273045
No abstract available.
8.
Giannikou K, Lasseter K, Grevelink J, Tyburczy M, Dies K, Zhu Z, et al.
Genet Med
. 2019 Jun;
21(11):2639-2643.
PMID: 31160751
Purpose: To examine the prevalence and spectrum of mosaic variant allele frequency (MVAF) in tuberous sclerosis complex (TSC) patients with low-level mosaicism and correlate genetic findings with clinical features and...
9.
Treichel A, Hamieh L, Nathan N, Tyburczy M, Wang J, Oyerinde O, et al.
Genet Med
. 2019 May;
21(11):2594-2604.
PMID: 31114024
Purpose: To determine if mosaic tuberous sclerosis complex (TSC) can be stratified into subtypes that correspond with prognosis and extent of disease. Methods: Next-generation sequencing of skin tumor and other...
10.
Hamieh L, Choueiri T, Ogorek B, Khabibullin D, Rosebrock D, Livitz D, et al.
PLoS Genet
. 2018 Sep;
14(9):e1007679.
PMID: 30256787
The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously....